Literature DB >> 24306005

The questionable use of unequal allocation in confirmatory trials.

Spencer Phillips Hey1, Jonathan Kimmelman.   

Abstract

Randomization is the standard means for addressing known and unknown confounders within the patient population in clinical trials. Although random assignment to treatment arms on a 1:1 basis has long been the norm, many 2-armed confirmatory trials now use unequal allocation schemes where the number of patients receiving investigational interventions exceeds those in the comparator arm. In what follows, we offer 3 arguments for why investigators, institutional review boards, and data and safety monitoring boards should exercise caution when planning or reviewing 2-armed confirmatory trials involving unequal allocation ratios. We close by laying out some of the conditions where uneven allocation can be justified ethically.

Entities:  

Mesh:

Year:  2013        PMID: 24306005      PMCID: PMC3873626          DOI: 10.1212/01.wnl.0000438226.10353.1c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  The use of unequal randomisation ratios in clinical trials: a review.

Authors:  J C Dumville; S Hahn; J N V Miles; D J Torgerson
Journal:  Contemp Clin Trials       Date:  2005-10-19       Impact factor: 2.226

Review 2.  Toward more efficient clinical trials for amyotrophic lateral sclerosis.

Authors:  Merit E Cudkowicz; Jon Katz; Dan H Moore; Gilmore O'Neill; Jonathan D Glass; Hiroshi Mitsumoto; Stanley Appel; Bernard Ravina; Karl Kieburtz; Ira Shoulson; Petra Kaufmann; Jaffar Khan; Ericka Simpson; Jeremy Shefner; Bruce Levin; Valerie Cwik; David Schoenfeld; Swati Aggarwal; Michael P McDermott; Robert G Miller
Journal:  Amyotroph Lateral Scler       Date:  2010-05-03

3.  Effects of expectation on placebo-induced dopamine release in Parkinson disease.

Authors:  Sarah C Lidstone; Michael Schulzer; Katherine Dinelle; Edwin Mak; Vesna Sossi; Thomas J Ruth; Raul de la Fuente-Fernández; Anthony G Phillips; A Jon Stoessl
Journal:  Arch Gen Psychiatry       Date:  2010-08

4.  Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.

Authors:  Jerry S Wolinsky; Ponnada A Narayana; Paul O'Connor; Patricia K Coyle; Corey Ford; Kenneth Johnson; Aaron Miller; Lillian Pardo; Shaul Kadosh; David Ladkani
Journal:  Ann Neurol       Date:  2007-01       Impact factor: 10.422

Review 5.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

Review 6.  Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials.

Authors:  A L Avins
Journal:  J Med Ethics       Date:  1998-12       Impact factor: 2.903

7.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

8.  Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.

Authors:  Joseph P Broderick; Yuko Y Palesch; Andrew M Demchuk; Sharon D Yeatts; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Frank L Silver; Rüdiger von Kummer; Carlos A Molina; Bart M Demaerschalk; Ronald Budzik; Wayne M Clark; Osama O Zaidat; Tim W Malisch; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Renée H Martin; Lydia D Foster; Thomas A Tomsick
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

9.  Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

Authors:  Peter A LeWitt; M Guttman; James W Tetrud; Paul J Tuite; Akihisa Mori; Philip Chaikin; Neil M Sussman
Journal:  Ann Neurol       Date:  2008-03       Impact factor: 10.422

Review 10.  A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries.

Authors:  Jonathan Kimmelman
Journal:  Trials       Date:  2012-09-22       Impact factor: 2.279

View more
  33 in total

1.  Are outcome-adaptive allocation trials ethical?

Authors:  Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

Review 2.  Ethical development of stem-cell-based interventions.

Authors:  Amanda MacPherson; Jonathan Kimmelman
Journal:  Nat Med       Date:  2019-07-03       Impact factor: 53.440

3.  A new era of treating advanced lung cancer is upon us.

Authors:  Glen J Weiss
Journal:  Transl Lung Cancer Res       Date:  2018-09

4.  Sequential rerandomization.

Authors:  Quan Zhou; Philip A Ernst; Kari Lock Morgan; Donald B Rubin; Anru Zhang
Journal:  Biometrika       Date:  2018-06-24       Impact factor: 2.445

5.  Ethical challenges in conducting clinical research in lung cancer.

Authors:  Peter Allmark; Angela M Tod
Journal:  Transl Lung Cancer Res       Date:  2016-06

6.  Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.

Authors:  Lata K McGinn; Anna Van Meter; Ian Kronish; Jessica Gashin; Karen Burns; Natalie Kil; Thomas G McGinn
Journal:  Cognit Ther Res       Date:  2019-02-12

Review 7.  Tiagabine add-on therapy for drug-resistant focal epilepsy.

Authors:  Rebecca Bresnahan; Kirsty J Martin-McGill; Jane L Hutton; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-10-14

8.  Brivaracetam add-on therapy for drug-resistant epilepsy.

Authors:  Rebecca Bresnahan; Mariangela Panebianco; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-03-28

9.  Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

Authors:  Aden C Feustel; Amanda MacPherson; Dean A Fergusson; Karl Kieburtz; Jonathan Kimmelman
Journal:  Neurology       Date:  2019-12-02       Impact factor: 9.910

10.  Adherence to Physiotherapy-Guided Web-Based Exercise for Persons with Moderate-to-Severe Multiple Sclerosis: A Randomized Controlled Pilot Study.

Authors:  Sarah J Donkers; Darren Nickel; Lorna Paul; Shyane R Wiegers; Katherine B Knox
Journal:  Int J MS Care       Date:  2020-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.